Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Clin Transl Oncol ; 20(3): 302-312, 2018 03.
Article in English | MEDLINE | ID: mdl-28808878

ABSTRACT

OBJECTIVE: Chronic intestinal inflammation is a risk factor for colorectal cancer (CRC) initiation and development. Diets that are rich in Western style fats have been shown to promote CRC. This study was conducted to investigate the role of intestinal microbiome in American ginseng-mediated CRC chemoprevention in a mouse model. The population and diversity of enteric microbiome were evaluated after the ginseng treatment. METHODS: Using an azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced gut inflammation and tumorigenesis mouse model, the effects of oral American ginseng on high fat diet-associated enteric pathology were determined. After establishment of a 16S rRNA illumina library from fecal samples, MiSeq sequencing was carried out to reveal the microbial population. The alpha and beta diversities of microbiome were analyzed. RESULTS: American ginseng significantly attenuated AOM/DSS-induced colon inflammation and tumorigenesis by reducing the colitis score and colon tumor multiplicity. The MiSeq results showed that the majority of sequences fell into three phyla: Firmicutes, Bacteroidetes and Verrucomicrobia. Further, two significant abundance shifts at the family level, Bacteroidaceae and Porphyromonadaceae, were identified to support ginseng's anti-colitis and anti-tumor effects. In addition, alpha and beta diversity data demonstrated that ginseng led to a profound recovery from the AOM/DSS-induced dysbiosis in the microbial community. CONCLUSION: Our results suggest that the CRC chemopreventive effects of American ginseng are mediated through enteric microbiome population-shift recovery and dysbiosis restoration. Ginseng's regulation of the microbiome balance contributes to the maintenance of enteric homeostasis.


Subject(s)
Carcinogenesis/drug effects , Colonic Neoplasms/pathology , Gastrointestinal Microbiome/drug effects , Panax , Plant Extracts/pharmacology , Animals , Azoxymethane/toxicity , Carcinogenesis/chemically induced , Carcinogenesis/pathology , Colitis/etiology , Colitis/microbiology , Colitis/pathology , Colonic Neoplasms/etiology , Colonic Neoplasms/microbiology , Dextran Sulfate/toxicity , Diet, High-Fat/adverse effects , Male , Mice , Plant Roots
3.
Zhonghua Gan Zang Bing Za Zhi ; 25(4): 268-272, 2017 Apr 20.
Article in Chinese | MEDLINE | ID: mdl-28494545

ABSTRACT

Objective: To investigate the regulatory effect of faciogenital dysplasia 6 (FGD6) gene on hepatic stem cell differentiation. Methods: FGD6 gene was selected for the co-intervention of target sequence, the AdEasy system was used for the construction of adenovirus vector and the packaging and multiplication of the recombinant adenovirus vector pSES-FGD6-siRNA, and the HP14.5 cells were infected. Immunofluorescence assay was used to measure the expression of FGD6 protein in HP14.5 cells, quantitative real-time PCR was used to measure the mRNA expression of FGD6, alpha-fetoprotein (AFP), and albumin (Alb), and Western blot was used to measure the protein expression of FGD6, AFP, and Alb. The empty pSES-Ad-RFP adenovirus vector was constructed as control in each group. All data were expressed as x±s, and a one-way analysis of variance was performed. Results: FGD6 protein was mainly expressed in the nucleus of HP14.5 cells. The pSES-FGD6-siRNA adenovirus vector was successfully constructed and it downregulated the expression of FGD6 gene and the mRNA and protein expression of AFP in HP14.5 cells and upregulated the mRNA and protein expression of Alb (P < 0.01). Conclusion: The inhibition of the expression of FGD6 gene in HP14.5 cells may differentiate HP14.5 cells into hepatocytes. Therefore, FGD6 gene plays an important role in the differentiation regulation of hepatic stem cells.


Subject(s)
Cell Differentiation/genetics , Dwarfism/genetics , Face/abnormalities , Genetic Diseases, X-Linked/genetics , Genitalia, Male/abnormalities , Hand Deformities, Congenital/genetics , Heart Defects, Congenital/genetics , Hepatocytes/cytology , Liver/cytology , Stem Cells/cytology , alpha-Fetoproteins/genetics , Albumins/genetics , Albumins/metabolism , Animals , Gene Expression , Hepatocytes/metabolism , Humans , Liver/metabolism , RNA, Messenger , Real-Time Polymerase Chain Reaction , Stem Cells/metabolism , alpha-Fetoproteins/metabolism
4.
Gene Ther ; 24(6): 333-341, 2017 06.
Article in English | MEDLINE | ID: mdl-28387759

ABSTRACT

Retroviral vectors including lentiviral vectors are commonly used tools to stably express transgenes or RNA molecules in mammalian cells. Their utilities are roughly divided into two categories, stable overexpression of transgenes and RNA molecules, which requires maximal transduction efficiency, or functional selection with retrovirus (RV)-based libraries, which takes advantage of retroviral superinfection resistance. However, the dynamic features of RV-mediated transduction are not well characterized. Here, we engineered two murine stem cell virus-based retroviral vectors expressing dual fluorescence proteins and antibiotic markers, and analyzed virion production efficiency and virion stability, dynamic infectivity and superinfection resistance in different cell types, and strategies to improve transduction efficiency. We found that the highest virion production occurred between 60 and 72 h after transfection. The stability of the collected virion supernatant decreased by >60% after 3 days in storage. We found that RV infectivity varied drastically in the tested human cancer lines, while low transduction efficiency was partially overcome with increased virus titer, prolonged infection duration and/or repeated infections. Furthermore, we demonstrated that RV receptors PIT1 and PIT2 were lowly expressed in the analyzed cells, and that PIT1 and/or PIT2 overexpression significantly improved transduction efficiency in certain cell lines. Thus, our findings provide resourceful information for the optimal conditions of retroviral-mediated gene delivery.


Subject(s)
Retroviridae/genetics , Transfection/methods , Animals , Cell Line, Tumor , Genes, Reporter , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Mice , Receptors, Virus/genetics , Receptors, Virus/metabolism , Retroviridae/metabolism , Retroviridae/pathogenicity , Transfection/standards , Virion/genetics , Virion/metabolism
5.
Zhonghua Fu Chan Ke Za Zhi ; 51(5): 361-5, 2016 May 25.
Article in Chinese | MEDLINE | ID: mdl-27256444

ABSTRACT

OBJECTIVE: The aim of this study is to evaluate the safety and efficacy of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer (EOC). METHODS: A total of 8 patients were recruited in this study who underwent partial pancreatectomy during the primary cytoreductive surgeries for advanced EOC in Fudan University Shanghai Cancer Center from April 2009 to July 2015. Their clinicopathological characteristics, diameter of metastatic tumors, the scope of cytoreductive surgeries, residual diseases after cytoreductive surgeries, postoperative complications and survival situation were retrospective analyzed. RESULTS: (1) Clinicopathological characteristics: the median age of these patients was 58 years old (range: 39-63 years old) . The median value of preoperative serum CA125 was 1 688 kU/L (range: 119-5 000 kU/L) . The median diameter of metastatic tumors involved in pancreatic body or tail was 4.5 cm (range: 3-10 cm). All the tumors from the 8 patients were confirmed to be high-grade serous carcinoma. Four patients were staged as International Federation of Gynecology and Obstetrics (FIGO) Ⅳ, and the other 4 patients were staged as FIGO Ⅲc. (2) Tumor metastases and the scope of cytoreductive surgeries: all of these 8 patients had widely disseminated ovarian cancer, with involvement of upper abdominal, middle abdominal and pelvic cavity. Each patient underwent extensive intra-abdominal cytoreductive surgeries, including hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic peritonectomy, splenectomy, partial pancreatectomy. Each patient had cytoreductive surgeries of 9.6 different sites on average. Of all 8 patients who underwent partial pancreatectomy, 7 patients had pancreatic tails removed; the other 1 patient had pancreatic body and tail removed. The median volume of blood loss during surgery was 1 350 ml (range: 300-3 500 ml) , blood transfusion was performed in 7 patients with the median volume of 1 150 ml (range: 500-1 800 ml). (3) Residual diseases after cytoreductive surgeries: optimal cytoreduction was achieved in all patients, with microscopic residual disease in 3 patients, residual tumors diameter < 0.5 cm in 3 patients, and residual tumors diameter between 0.5 and 1 cm in 2 patients. (4) Postoperative complications: 4 patients suffered from complications including pancreatic leakage (2/8), intraperitoneal hemorrhage (1/8) and pancreatic pseudocyst accompanied by infection (1/8). These complications were treated successfully by conservative managements. (5) Survival situation: during the median follow-up duration of 17 months (ranged from 2 to 46 months), 5 patients were still alive until the end of follow-up, including 4 cases under treatment and 1 case survived 29 months without relapse after treatment. Three patients were respectively died in 5, 20 and 46 months after surgery. CONCLUSION: There is a higher risk of postoperative complications of pancreas resection as part of primary cytoreductive surgery in advanced epithelial ovarian cancer, but the resection of pancreatic metastases and part of the pancreas is feasible and necessary.


Subject(s)
Cytoreduction Surgical Procedures , Neoplasms, Glandular and Epithelial/surgery , Ovarian Neoplasms/surgery , Pancreatectomy , Adult , Animals , Carcinoma, Ovarian Epithelial , Female , Humans , Hysterectomy , Middle Aged , Neoplasm Recurrence, Local , Neoplasm, Residual , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/pathology , Ovariectomy , Retrospective Studies
6.
Genes Dis ; 1(1): 1-3, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25374930
7.
Gene Ther ; 21(7): 629-37, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24784448

ABSTRACT

Recombinant adenoviruses are one of the most common vehicles for efficient in vitro and in vivo gene deliveries. Here, we investigate whether exogenous precursor terminal protein (pTP) expression in 293 cells improves the efficiency of adenovirus packaging and amplification. We used a piggyBac transposon-based vector and engineered a stable 293 line that expresses high level of Ad5 pTP, designated as 293pTP. Using the AdBMP6-GLuc that expresses green fluorescent protein (GFP), BMP6 and Gaussia luciferase, we found that the infectivity of AdBMP6-GLuc viral samples packaged in 293pTP cells was titrated up to 19.3 times higher than that packaged in parental 293 cells. AdBMP6-GLuc viral samples packaged in 293pTP cells exhibited significantly higher transduction efficiency in 143B and immortalized mouse embryonic fibroblast (iMEF) cells, as assessed by fluorescence-activated cell sorting analysis of GFP-positive cells, the luciferase activity assay and BMP6-induced osteogenic marker alkaline phosphatase activities in iMEFs. When adenovirus amplification efficiency was analyzed, we found that 293pTP cells infected with AdBMP6-GLuc yielded up to 12.6 times higher titer than that in parental 293 cells, especially at lower multiplicities of infection. These results strongly suggest that exogenous pTP expression may accelerate the packaging and amplification of recombinant adenoviruses. Thus, the engineered 293pTP cells should be a superior packaging line for efficient adenovirus production.


Subject(s)
Adenoviridae/physiology , Phosphoproteins/metabolism , Protein Precursors/metabolism , Viral Proteins/metabolism , Virus Assembly , Adenoviridae/genetics , Adenoviridae Infections/virology , Animals , Cell Line, Tumor , Embryo, Mammalian/metabolism , Fibroblasts/cytology , Fibroblasts/virology , Genetic Vectors , HEK293 Cells , Humans , Mesenchymal Stem Cells/virology , Mice , Recombination, Genetic , Transduction, Genetic
8.
Braz J Med Biol Res ; 46(7): 559-66, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23903683

ABSTRACT

Hepatic progenitor cells (HPCs) are a potential cell source for liver cell transplantation but do not function like mature liver cells. We sought an effective and reliable method to induce HPC maturation. An immortalized HP14.5 albumin promoter-driven Gaussian luciferase (ALB-GLuc) cell line was established from HPCs isolated from fetal mouse liver of post coitus day 14.5 mice to investigate the effect of induction factors on ALB promoter. HP14.5 parental cells were cultured in DMEM with different combinations of 2% horse serum (HS), 0.1 µM dexamethasone (DEX), 10 ng/mL hepatic growth factor (HGF), and/or 20 ng/mL fibroblast growth factor 4 (FGF4). Trypan blue and crystal violet staining were used to assess cell proliferation with different induction conditions. Expression of hepatic markers was measured by semi-quantitative RT-PCR, Western blot, and immunofluorescence. Glycogen storage and metabolism were detected by periodic acid-Schiff and indocyanine green (ICG) staining. GLuc activity indicated ALB expression. The combination of 2% HS+0.1 µM Dex+10 ng/mL HGF+20 ng/mL FGF4 induced the highest ALB-GLuc activity. Cell proliferation decreased in 2% HS but increased by adding FGF4. Upon induction, and consistent with hepatocyte development, DLK, AFP, and CK19 expression decreased, while ALB, CK18, and UGT1A expression increased. The maturity markers tyrosine aminotransferase and apolipoprotein B were detected at days 3 and 6 post-induction, respectively. ICG uptake and glycogen synthesis were detectable at day 6 and increased over time. Therefore, we demonstrated that HPCs were induced to differentiate into functional mature hepatocytes in vitro, suggesting that factor-treated HPCs may be further explored as a means of liver cell transplantation.


Subject(s)
Cell Differentiation/drug effects , Embryo, Mammalian/drug effects , Hepatocytes/cytology , Liver/cytology , Stem Cells/drug effects , Animals , Antigens, Differentiation/analysis , Apolipoprotein B-100 , Apolipoproteins B/isolation & purification , Cell Proliferation , Dexamethasone/administration & dosage , Fibroblast Growth Factors/administration & dosage , Gentian Violet , Glycogen/metabolism , Hepatocyte Growth Factor/administration & dosage , Indocyanine Green/pharmacokinetics , Mice , Primary Cell Culture/methods , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/cytology , Trypan Blue , Tyrosine Transaminase/isolation & purification
9.
Braz. j. med. biol. res ; 46(7): 559-566, ago. 2013. graf
Article in English | LILACS | ID: lil-682396

ABSTRACT

Hepatic progenitor cells (HPCs) are a potential cell source for liver cell transplantation but do not function like mature liver cells. We sought an effective and reliable method to induce HPC maturation. An immortalized HP14.5 albumin promoter-driven Gaussian luciferase (ALB-GLuc) cell line was established from HPCs isolated from fetal mouse liver of post coitus day 14.5 mice to investigate the effect of induction factors on ALB promoter. HP14.5 parental cells were cultured in DMEM with different combinations of 2% horse serum (HS), 0.1 µM dexamethasone (DEX), 10 ng/mL hepatic growth factor (HGF), and/or 20 ng/mL fibroblast growth factor 4 (FGF4). Trypan blue and crystal violet staining were used to assess cell proliferation with different induction conditions. Expression of hepatic markers was measured by semi-quantitative RT-PCR, Western blot, and immunofluorescence. Glycogen storage and metabolism were detected by periodic acid-Schiff and indocyanine green (ICG) staining. GLuc activity indicated ALB expression. The combination of 2% HS+0.1 µM Dex+10 ng/mL HGF+20 ng/mL FGF4 induced the highest ALB-GLuc activity. Cell proliferation decreased in 2% HS but increased by adding FGF4. Upon induction, and consistent with hepatocyte development, DLK, AFP, and CK19 expression decreased, while ALB, CK18, and UGT1A expression increased. The maturity markers tyrosine aminotransferase and apolipoprotein B were detected at days 3 and 6 post-induction, respectively. ICG uptake and glycogen synthesis were detectable at day 6 and increased over time. Therefore, we demonstrated that HPCs were induced to differentiate into functional mature hepatocytes in vitro, suggesting that factor-treated HPCs may be further explored as a means of liver cell transplantation.


Subject(s)
Animals , Mice , Cell Differentiation/drug effects , Embryo, Mammalian/drug effects , Hepatocytes/cytology , Liver/cytology , Stem Cells/drug effects , Antigens, Differentiation/analysis , Apolipoproteins B/isolation & purification , Cell Proliferation , Dexamethasone/administration & dosage , Fibroblast Growth Factors/administration & dosage , Gentian Violet , Glycogen/metabolism , Hepatocyte Growth Factor/administration & dosage , Indocyanine Green/pharmacokinetics , Primary Cell Culture/methods , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/cytology , Trypan Blue , Tyrosine Transaminase/isolation & purification
10.
Cell Death Dis ; 3: e376, 2012 Aug 23.
Article in English | MEDLINE | ID: mdl-22914324

ABSTRACT

Falcarindiol (FAD) is a natural polyyne with various beneficial biological activities. We show here that FAD preferentially kills colon cancer cells but not normal colon epithelial cells. Furthermore, FAD inhibits tumor growth in a xenograft tumor model and exhibits strong synergistic killing of cancer cells with 5-fluorouracil, an approved cancer chemotherapeutic drug. We demonstrate that FAD-induced cell death is mediated by induction of endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR). Decreasing the level of ER stress, either by overexpressing the ER chaperone protein glucose-regulated protein 78 (GRP78) or by knockout of components of the UPR pathway, reduces FAD-induced apoptosis. In contrast, increasing the level of ER stress by knocking down GRP78 potentiates FAD-induced apoptosis. Finally, FAD-induced ER stress and apoptosis is correlated with the accumulation of ubiquitinated proteins, suggesting that FAD functions at least in part by interfering with proteasome function, leading to the accumulation of unfolded protein and induction of ER stress. Consistent with this, inhibition of protein synthesis by cycloheximide significantly decreases the accumulation of ubiquitinated proteins and blocks FAD-induced ER stress and cell death. Taken together, our study shows that FAD is a potential new anticancer agent that exerts its activity through inducing ER stress and apoptosis.


Subject(s)
Antineoplastic Agents, Phytogenic/toxicity , Apoptosis/drug effects , Diynes/toxicity , Endoplasmic Reticulum Stress/drug effects , Fatty Alcohols/toxicity , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Cell Line, Tumor , Colorectal Neoplasms/drug therapy , Diynes/therapeutic use , Drug Synergism , Endoplasmic Reticulum Chaperone BiP , Fatty Alcohols/therapeutic use , Fluorouracil/toxicity , HCT116 Cells , Heat-Shock Proteins/antagonists & inhibitors , Heat-Shock Proteins/genetics , Heat-Shock Proteins/metabolism , Humans , Mice , Transplantation, Heterologous , Ubiquitination/drug effects , Unfolded Protein Response/drug effects
11.
Oncogene ; 30(37): 3907-17, 2011 Sep 15.
Article in English | MEDLINE | ID: mdl-21460855

ABSTRACT

Osteosarcoma (OS) is the most common primary malignancy of bone. There is a critical need to identify the events that lead to the poorly understood mechanism of OS development and metastasis. The goal of this investigation is to identify and characterize a novel marker of OS progression. We have established and characterized a highly metastatic OS subline that is derived from the less metastatic human MG63 line through serial passages in nude mice via intratibial injections. Microarray analysis of the parental MG63, the highly metastatic MG63.2 subline, as well as the corresponding primary tumors and pulmonary metastases revealed insulin-like growth factor binding protein 5 (IGFBP5) to be one of the significantly downregulated genes in the metastatic subline. Confirmatory quantitative RT-PCR on 20 genes of interest demonstrated IGFBP5 to be the most differentially expressed and was therefore chosen to be one of the genes for further investigation. Adenoviral mediated overexpression and knockdown of IGFBP5 in the MG63 and MG63.2 cell lines, as well as other OS lines (143B and MNNG/HOS) that are independent of our MG63 lines, were employed to examine the role of IGFBP5. We found that overexpression of IGFBP5 inhibited in vitro cell proliferation, migration and invasion of OS cells. Additionally, IGFBP5 overexpression promoted apoptosis and cell cycle arrest in the G1 phase. In an orthotopic xenograft animal model, overexpression of IGFBP5 inhibited OS tumor growth and pulmonary metastases. Conversely, siRNA-mediated knockdown of IGFBP5 promoted OS tumor growth and pulmonary metastases in vivo. Immunohistochemical staining of patient-matched primary and metastatic OS samples demonstrated decreased IGFBP5 expression in the metastases. These results suggest 1) a role for IGFBP5 as a novel marker that has an important role in the pathogenesis of OS, and 2) that the loss of IGFBP5 function may contribute to more metastatic phenotypes in OS.


Subject(s)
Bone Neoplasms/metabolism , Insulin-Like Growth Factor Binding Protein 5/metabolism , Lung Neoplasms/metabolism , Osteosarcoma/metabolism , Adolescent , Adult , Animals , Apoptosis , Bone Neoplasms/genetics , Bone Neoplasms/pathology , Cell Line, Tumor , Cell Movement , Cell Proliferation , Child , Down-Regulation , Female , Gene Expression Profiling , Gene Knockdown Techniques , Humans , Insulin-Like Growth Factor Binding Protein 5/genetics , Lung Neoplasms/genetics , Lung Neoplasms/secondary , Male , Mice , Mice, Nude , Osteosarcoma/genetics , Osteosarcoma/secondary , Young Adult
12.
Neoplasma ; 56(2): 119-23, 2009.
Article in English | MEDLINE | ID: mdl-19239325

ABSTRACT

UNLABELLED: The binding of the Wnt ligand to its receptor Frizzled, activates the Wnt canonical signaling pathway in carcinogenesis as well as many cellular processes, including cellular proliferation and differentiation. Wnt-2, one of 19 members of the Wnt gene family, is frequently overexpressed in malignant tissues. Here, in order to investigate the role of Wnt-2 in colorectal carcinogenesis, we examined the expression of the Wnt-2 protein in 120 colorectal cancers by immunohistochemistry. Wnt-2 protein was expressed in the cell membrane and cytoplasm and up-regulated in 74 (61.7%) of 120 colorectal cancers. Statistically, overexpression of Wnt-2 protein was not associated with the clinical and pathological parameters studied, including tumor location, tumor size, clinical stage, lymph node metastasis, and 5-year survival (P > 0.05). These results indicate that up-regulation of the Wnt-2 protein might play a role in the development of colorectal cancers, as an early event of carcinogenesis. KEYWORDS: Wnt-2 protein, expression, immunohistochemistry, tissue microarray, colon cancer.


Subject(s)
Colorectal Neoplasms/chemistry , Wnt2 Protein/analysis , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Humans , Immunohistochemistry , Survival Rate , Wnt2 Protein/physiology
14.
Hand Clin ; 21(2): 267-73, 2005 May.
Article in English | MEDLINE | ID: mdl-15882605

ABSTRACT

Clinical outcomes following flexor tendon repair have made significant improvements in the last 50 years. In that time standard treatment has evolved from secondary grafting to primary repair with postoperative rehabilitation protocols. Unfortunately, excellent results are not yet attained universally following treatment. Improving understanding of tendon healing at the cellular, molecular, and genetic levels will likely enable surgeons to modulate the normal repair process. We now look toward biologic augmentation of flexor tendon repairs to address the problems of increasing tensile strength while reducing adhesion formation following injury and operative repair.


Subject(s)
Hand Injuries/surgery , Orthopedic Procedures/trends , Tendon Injuries/surgery , Genetic Therapy , Humans , Mesenchymal Stem Cell Transplantation , Molecular Biology , Orthopedic Procedures/methods , Tissue Engineering
15.
Gene Ther ; 11(17): 1312-20, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15269709

ABSTRACT

Efficacious bone regeneration could revolutionize the clinical management of bone and musculoskeletal disorders. Although several bone morphogenetic proteins (BMPs) (mostly BMP-2 and BMP-7) have been shown to induce bone formation, it is unclear whether the currently used BMPs represent the most osteogenic ones. Until recently, comprehensive analysis of osteogenic activity of all BMPs has been hampered by the fact that recombinant proteins are either not biologically active or not available for all BMPs. In this study, we used recombinant adenoviruses expressing the 14 types of BMPs (AdBMPs), and demonstrated that, in addition to currently used BMP-2 and BMP-7, BMP-6 and BMP-9 effectively induced orthotopic ossification when either AdBMP-transduced osteoblast progenitors or the viral vectors were injected into the quadriceps of athymic mice. Radiographic and histological evaluation demonstrated that BMP-6 and BMP-9 induced the most robust and mature ossification at multiple time points. BMP-3, a negative regulator of bone formation, was shown to effectively inhibit orthotopic ossification induced by BMP-2, BMP-6, and BMP-7. However, BMP-3 exerted no inhibitory effect on BMP-9-induced bone formation, suggesting that BMP-9 may transduce osteogenic signaling differently. Our findings suggest that BMP-6 and BMP-9 may represent more effective osteogenic factors for bone regeneration.


Subject(s)
Adenoviridae/genetics , Bone Diseases/therapy , Bone Morphogenetic Proteins/genetics , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Osteogenesis/genetics , Animals , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 6 , Bone Morphogenetic Protein 7 , Cell Line , Genetic Vectors/genetics , Growth Differentiation Factor 2 , Injections, Intramuscular , Male , Mice , Mice, Nude , Reverse Transcriptase Polymerase Chain Reaction , Transforming Growth Factor beta/genetics
16.
Biotechniques ; 33(5): 1126-8, 1130, 1132 passim, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12449394

ABSTRACT

Aberrant activation of beta-catenin signaling has been implicated in the development of human cancers. As a Wnt signal transducer, beta-catenin forms a complex with the lymphocyte enhancer-binding factor/T cell factor transcription factor and activates downstream targets that promote cell proliferation. Here we developed a Wnt-dependent beta-catenin-mediated heterologous transactivation system, which consisted of a chimeric transcription factor constructed by fusing the GAL4 DNA-binding domain with the full-length beta-catenin, and a GAL4-responsive reporter expressing GFP. The chimeric transcription factor was highly unstable and exerted no detectable transactivating effect on the GAL4-responsive reporter. However, lithium and Wnt1 significantly stabilized this chimeric transactivator, indicating that this transactivation system is regulated by beta-catenin in a Wnt-responsive fashion. Thus, this transactivation system could be used as a functional reporter to identify potential upstream factors that deregulate beta-catenin signaling during tumorigenesis, as well as to screen for potential anti-cancer agents that specifically inhibit beta-catenin signaling in human tumors.


Subject(s)
Cytoskeletal Proteins/physiology , Fluorometry/methods , Luminescent Proteins/analysis , Proto-Oncogene Proteins/physiology , Signal Transduction , Trans-Activators/physiology , Transcriptional Activation , Zebrafish Proteins , Adenocarcinoma/pathology , Adenoviridae/genetics , Animals , Bone Neoplasms , Cell Line , Chondrosarcoma/pathology , Colonic Neoplasms/pathology , Culture Media, Conditioned/pharmacology , Cytoskeletal Proteins/antagonists & inhibitors , DNA-Binding Proteins , Genes, Reporter , Genetic Vectors/genetics , Green Fluorescent Proteins , Humans , Kidney , Luciferases/analysis , Luciferases/biosynthesis , Luciferases/genetics , Luminescent Proteins/biosynthesis , Luminescent Proteins/genetics , Mice , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/physiology , Osteosarcoma/pathology , Protein Structure, Tertiary , Recombinant Fusion Proteins/physiology , Saccharomyces cerevisiae Proteins/genetics , Trans-Activators/antagonists & inhibitors , Transcription Factors/genetics , Transfection , Tumor Cells, Cultured , Wnt Proteins , Wnt1 Protein , beta Catenin
18.
J Biol Chem ; 276(48): 45168-74, 2001 Nov 30.
Article in English | MEDLINE | ID: mdl-11581265

ABSTRACT

Regulated gene expression will provide important platforms from which gene functions can be investigated and safer means of gene therapy may be developed. Histone deacetylases have recently been shown to play an important role in regulating gene expression. Here we investigated whether a more tightly controlled expression could be achieved by using a novel chimeric repressor that recruits histone deacetylases to a tetracycline-responsive promoter. This chimeric repressor was engineered by fusing the tetracycline repressor (TetR) with an mSin3-interacting domain of human Mad1 and was shown to bind the tetO(2) element with high affinity, and its binding was efficiently abrogated by doxycycline. The chimeric repressor was shown to directly interact with mSin3 of the histone deacetylase complex. This inducible system was further simplified by using a single vector that contained both a chimeric repressor expression cassette and a tetracycline-responsive promoter. When transiently introduced into mammalian cells, the chimeric repressor system exhibited a significantly lower basal level of luciferase activity (up to 25-fold) than that of the TetR control. When stably transfected into HEK 293 cells, the chimeric repressor system was shown to exert a tight control of green fluorescent protein expression in a doxycycline dose- and time-dependent fashion. Therefore, this novel chimeric repressor provides an effective means for more tightly regulated gene expression, and the simplified inducible system may be used for a broad range of basic and clinical studies.


Subject(s)
Gene Expression Regulation, Enzymologic , Histone Deacetylases/metabolism , Tetracycline/pharmacology , Base Sequence , Cell Cycle Proteins , Cell Line , Genetic Vectors , Gentamicins/pharmacology , Glutathione Transferase/metabolism , Green Fluorescent Proteins , Humans , Kinetics , Luciferases/metabolism , Luminescent Proteins/metabolism , Microscopy, Fluorescence , Molecular Sequence Data , Nuclear Proteins , Phosphoproteins/chemistry , Phosphoproteins/metabolism , Promoter Regions, Genetic , Protein Binding , Protein Structure, Tertiary , Recombinant Fusion Proteins/metabolism , Repressor Proteins/chemistry , Repressor Proteins/metabolism , Sin3 Histone Deacetylase and Corepressor Complex , Time Factors , Transfection , Tumor Cells, Cultured
19.
Curr Opin Oncol ; 13(1): 78-83, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11148691

ABSTRACT

Peroxisome proliferator-activated receptors are nuclear receptors that were isolated for their ability to modulate lipid metabolism. Similar to other members of the nuclear receptor family, peroxisome proliferator-activated receptors bind ligand as heterodimers and exert their effects via transcriptional regulation through their DNA binding domains. During the past decade, it has become clear that peroxisome proliferator-activated receptors also contribute to a variety of different biologic processes, including atherosclerosis, insulin resistance, and more recently, cancer. In this review, we discuss the evidence for the different peroxisome proliferator-activated receptors' roles in tumorigenesis and also their potential application for the treatment and prevention of neoplastic diseases.


Subject(s)
Cell Transformation, Neoplastic , Peroxisome Proliferators/pharmacology , Adenomatous Polyposis Coli/physiopathology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Binding Sites/physiology , Cell Nucleus/physiology , Chemoprevention , Humans , Ligands
20.
Curr Gene Ther ; 1(2): 149-62, 2001 Jul.
Article in English | MEDLINE | ID: mdl-12108952

ABSTRACT

Human gene therapy promises to change the practice of medicine by treating the causes of disease rather than the symptoms. Since the first clinical trial made its debut ten years ago, there are over 400 approved protocols in the United States alone, most of which have failed to show convincing data of clinical efficacy. This setback is largely due to the lack of efficient and adequate gene transfer vehicles. With the recent progress in elucidating the molecular mechanisms of human diseases and the imminent arrival of the post genomic era, there are increasing numbers of therapeutic genes or targets that are available for gene therapy. Therefore, the urgency and need for efficacious gene therapies are greater than ever. Clearly, the current fundamental obstacle is to develop delivery vectors that exhibit high efficacy and specificity of gene transfer. Recombinant adenoviruses have provided a versatile system for gene expression studies and therapeutic applications. Of late, there has been a remarkable increase in adenoviral vector-based clinical trials. Recent endeavors in the development of recombinant adenoviral vectors have focused on modification of virus tropism, accommodation of larger genes, increase in stability and control of transgene expression, and down-modulation of host immune responses. These modifications and continued improvements in adenoviral vectors will provide a great opportunity for human gene therapy to live up to its enormous potential in the second decade.


Subject(s)
Adenoviridae/genetics , Gene Transfer Techniques , Genetic Therapy/methods , Genetic Vectors , Adenoviridae/physiology , Animals , Biotechnology , Cardiovascular Diseases/therapy , Clinical Trials as Topic , Genetic Diseases, Inborn/therapy , Humans , Liver Diseases/genetics , Liver Diseases/therapy , Neoplasms/therapy , Neurodegenerative Diseases/therapy , Recombination, Genetic , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...